Schall, Brown & Schwartz LLP is reminding investors about a securities class action against Aardvark Therapeutics, Inc. (NASDAQ: AARD), alleging violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5, a rule addressing securities fraud, promulgated by the U.S. Securities and Exchange Commission (SEC), the U.S. securities regulator. The allegations concern statements made during and traceable to Aardvark’s February 13, 2025, initial public offering (IPO), and during the period from February 13, 2025, through May 14, 2026. The complaint alleges that Aardvark misled investors about the safety profile of its ARD-101 drug candidate and overstated the candidate’s clinical and commercial prospects. The firm says investors suffered losses after the market learned what it described as the truth about Aardvark. Shareholders who purchased AARD shares during the relevant period and suffered a loss are encouraged to contact the firm by October 13, 2026, regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to participate in any recovery. The class has not yet been certified, and investors who take no action may remain absent class members.